Patent Grant
8653122
The present invention relates to an oromucosal formulation comprising as an active ingredient a substituted imidazole derivative of formula (I)
wherein Y is —CH2— or —CO—, R1 is halogen or hydroxy, R2 is H or halogen and R3 is H or lower alkyl, or an acid addition salt thereof.
The invention also relates to a process for preparing the oromucosal formulation in question.
The compounds of the above-mentioned formula (I) are highly selective and long-acting antagonists of α2-adrenoceptors. The compounds are especially valuable in the treatment of cognitive disorders. Compounds of formula (I) and their preparation have been described in patent publication EP 0 618 906 B1. Specific examples of such compounds are 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole, i.e. fipamezole, and 4-(5-fluoroindan-2-yl)-1H-imidazole.
Although the compounds of formula (I) and their salts have good properties as such, they have disadvantages, when formulated for conventional oral administration, i.e. the normal route for administering said compounds. A problem is that the compounds rather quickly decompose in the gastrointestinal area or other body systems prior to accessing systemic blood flow and the therapeutic target organs. This in turn significantly lowers the effect of the compounds in question.
Toxicology studies carried out with dogs (see Example 8) have further suggested that cardiac safety considerations are of importance whereas QT prolongation was observed with high oral doses of fipamezole when the systemic concentration of fipamezole reached about 2000 ng/ml.
One object of the present invention is to provide a formulation for administering compounds of formula (I) safely and efficiently.
Another object of the present invention is to provide a process for preparing the formulation.
Thus, according to one aspect of this invention concerns an oromucosal formulation comprising as an active ingredient a substituted imidazole derivative of formula (I)
where Y is —CH2— or —CO—, R1 is halogen or hydroxy, R2 is H or halogen and R3 is H or lower alkyl, or an acid addition salt thereof, together with additives conventionally used in oromucosal formulations.
According to another aspect, the invention concerns a process for preparing the oromucosal formulation.
It has now surprisingly been found that the problems of quick decomposition in the gastrointestinal area and compromised cardiac safety of the compounds of formula (I) can be alleviated by formulating the compounds of formula (I) into oromucosal formulations. Such formulations are effective and easy to handle, and therefore they have an advantage in terms of practical administration to the patient.
Suitable additives to be used in the formulation according to the present invention are adjuvants, excipients etc. including solvents, preserving agents, flavouring agents, fillers, gelling agents and mucoadhesive polymers. Preferred solvents are alcohols, especially ethanol, water and mixtures thereof. Preferred preserving agents are lower alkyl parahydroxybenzoates, especially methyl and propyl parahydroxybenzoate, and mixtures thereof. Preferred flavouring agents are aspartame, artificial flavours, such as black currant 502.009, and mixtures thereof.
In this context, the oromucosal formulation means any type of formulation administered via oral mucosa. Such formulations include e.g. sprays, gels, mucoadhesive buccal tablets and pastes, sublingual tablets and like. The formulation is preferably in the form of a spray.
In this context, the term halogen refers to F, Cl, Br and I, preferably to F and Cl and most preferably to F.
In this context, the term lower alkyl refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms and most preferably 1 or 2 carbon atoms.
In this context, the term an acid addition salt refers to an addition salt of any pharmaceutically acceptable acid, preferably hydrochloric acid.
In this context, the term an additive conventionally used in oromucosal formulations refers to any additive known by the person skilled in the art to be applicable for oromucosal formulations.
An especially preferred active ingredient is fipamezole (JP-1730, 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole hydrochloride). A formulation containing said preferred active ingredient is prepared according to the invention by mixing and dissolving ethanol (96%), purified water, methylparahydroxybenzoate, propylparahydroxybenzoate and aspartame at room temperature, at +15 to +25° C. Followed by adding and dissolving 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole and artificial flavour, such as black currant 502.009A, at room temperature, at +15 to +25° C. The volume of the mixture is adjusted with purified water, followed by filtering and the desired spray formulation is recovered.
The following examples illustrate the invention, but are not intended to restrict the scope of the invention.
Spray Formulation Containing 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole hydrochloride (fipamezole)
Fipamezole Oromucosal Spray
Spray Formulation Containing 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole hydrochloride (fipamezole)
Fipamezole Oromucosal Spray
Preparation of a Spray Formulation Containing 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole hydrochloride (fipamezole)
416.0 ml of ethanol (96%) was mixed with 450.0 ml of purified water to form a homogenous mixture. 1.80 g of methylparahydroxybenzoate, 0.20 g of propylparahydroxybenzoate and 0.5 g of aspartame were added to the mixture and dissolved at room temperature, at +15 to +25° C. 15.0 g of fipamezole, 0.4 g of black currant flavour were added to the mixture and dissolved at room temperature, at +15 to +25° C. The volume of the mixture was adjusted to 1000.0 ml with purified water. The solution was filtered and the desired spray formulation was recovered.
Preparation of an Oromucosal Gel Formulation Containing 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole hydrochloride (fipamezole) 30 mg
Composition
Method of Preparation
Fipamezole (1) and ethanol (96%) (2) are mixed and dissolved to form a solution A. Purified water (6), poloxamer 407 (3), liquid flavour (4), and aspartame (5) are mixed and dissolved to form a solution B. Solution A and solution B are cooled down to approx. +5° C., and mixed together to form a homogenous solution. Oromucosal gel formulation is recovered.
Preparation of a Mucoadhesive Buccal Tablet Formulation Containing 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole hydrochloride fipamezole) 30 mg
Composition
Method of Preparation
Fipamezole (1), carbomer 934P (2), hydroxypropylmethyl-cellulose (3), flavour (4), aspartame (5), and magnesium stearate (6) are mixed to form a homogenous mixture. The mixture is compressed to tablets of a suitable size. Mucoadhesive buccal tablets are recovered.
Preparation of a Sublingual Tablet Formulation Containing 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole hydrochloride (fipamezole) 30 mg
Composition
Method of Preparation
Fipamezole (1), lactose monohydrate (2), flavour (5), and aspartame (6) are mixed to form a homogenous mixture. The mixture is granulated with 10% aqueous solution of povidone (3). Granules are formed in either high-shear or low-shear mixer. Granulated mixture is let to dry. Dry, granulated mixture is passed through a screen to obtain freely flowing granulate. Microcrystalline cellulose (4) and magnesium stearate (7) are mixed with the granulate. The final blend is compressed to tablets of a suitable size. Sublingual tablets are recovered.
Oromucosal Delivery of Fipamezole
Plasma levels of fipamezole were studied in healthy male volunteers after oral administration of the drug as a solution. Blood samples for pharmcokinetic evaluation were collected for 24 hours after the drug administration. The concentration of fipamezole in plasma was measured with HPLC-MS/MS, and the pharmacokinetic parameters were calculated. The pharmacokinetics of fipamezole was evaluated with TopFit 2.0 pharmacokinetic program. The Cmax and tmax values were read from the concentration vs. time curves, and the apparent elimination phase half-lives from the terminal part of the semilogarithmic concentration vs. time curve (see
Mean plasma concentration time plot following single dose administration of 30 mg fipamezole via an oral, oromucosal spray and an oromucosal tablet on a semilogarithmic scale is shown in
Cardiac Safety
Cardiac safety was studied in dogs in a 30-day dog toxicology study using oral dosing and dog toxicology studies using buccal dosing.
In the 30-day dog toxicology study fipamezole was administered orally at doses of 1, 5, 10 and 15 mg/kg/day for 30 days, resulting in maximum systemic fipamezole concentrations of about 200, 1000, 2000 and 3300 ng/ml, respectively. These in vivo results in the dog suggested that QT prolongation was observed when the systemic concentration of fipamezole reached about 2000 ng/ml.
In another toxicology study four male dogs were given fipamezole in buccal spray doses of 1, 5 and 10 mg/kg in a sequential dosing regimen with 5 to 15 days between doses. Blood pressure (systolic, diastolic and mean), heart rate and ECGs were monitored before and up to 12 hours after dosing. At 30 minutes after dosing with 5 and 10 mg/kg significant transient increases in absolute values for blood pressure and heart rate were observed. No ECG changes (P wave amplitude, P wave duration, P-Q interval, QRS interval or Q-T [Q-Tcv, QTc] interval) were apparent after fipamezole dosing at each dose level.
Yet another toxicology study using buccal delivery to dogs at dose levels of 1, 5 and 10 mg/kg/day for up to 4 weeks showed no apparent changes in ECG. Maximum systemic concentrations of fipamezole after dosing on the first day of this study were about 800, 2000 and 3300 ng/ml.
| Number | Date | Country | Kind |
|---|---|---|---|
| 20022007 | Nov 2002 | FI | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/FI03/00850 | 11/10/2003 | WO | 00 | 5/6/2005 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2004/041271 | 5/21/2004 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 4855326 | Fuisz | Aug 1989 | A |
| 5079018 | Ecanow | Jan 1992 | A |
| 5298261 | Pebley et al. | Mar 1994 | A |
| 5434177 | Riekkinen et al. | Jul 1995 | A |
| 5466464 | Masaki et al. | Nov 1995 | A |
| 5498623 | Karjalainen et al. | Mar 1996 | A |
| 5541211 | Pertovaara et al. | Jul 1996 | A |
| 5658938 | Geerts et al. | Aug 1997 | A |
| 5948430 | Zerbe et al. | Sep 1999 | A |
| 6284270 | Lagoviyer et al. | Sep 2001 | B1 |
| 6316026 | Tatara et al. | Nov 2001 | B1 |
| 6326401 | Chauveau et al. | Dec 2001 | B1 |
| 6375982 | Cherukuri | Apr 2002 | B1 |
| 6413988 | De Proost | Jul 2002 | B1 |
| 6552024 | Chen et al. | Apr 2003 | B1 |
| 6669957 | Laruelle et al. | Dec 2003 | B1 |
| 6696085 | Rault et al. | Feb 2004 | B2 |
| 20040236108 | Smith et al. | Nov 2004 | A1 |
| Number | Date | Country |
|---|---|---|
| 0 204 045 | Dec 1986 | EP |
| 0 914 818 | May 1999 | EP |
| 1548022 | Jul 1979 | GB |
| WO 9104757 | Apr 1991 | WO |
| WO 9313074 | Jul 1993 | WO |
| WO 0067694 | Nov 2000 | WO |
| WO 0239991 | May 2002 | WO |
| WO 03030881 | Apr 2003 | WO |
| Entry |
|---|
| Funck-Bretano et al. Circulation 1991;83;536-545. |
| Huupponen et al., “Buccal Delivery of an α2-adrenergic Receptor Antagonist, Atipamezole, in Humans,” 58 Clin Pharmacol Ther 506 (1995). |
| Farmos, “Atipamezole Antisedan®,” 21 Drugs of the Future 534 (1996). |
| Sorbera et al., “Fipamezole Hydrochloride,” 28 Drugs of the Future 14 (2003). |
| Penttila et al., “Effects of Atipamezole—A Selective α2-Adrenoceptor Antagonist—on Cardiac Parasympathetic Regulation in Human Subjects,” 24 Autonomic & Autocoid Pharm. 69-75. |
| Takuri et al., “Preservation of Dispersed Systems,” 2 Pharmaceutical Dosage Forms 73-114 (Lieberman, Rieger and Banker eds. 1989). |
| Crouch et al., “Clinical Relevance and Management of Drug-Related QT Interval Prolongation,” 23 Pharmacotherapy 881-908 (2003). |
| Myerburg, ch 232 “Electrocariography”, Harrison's Internal Medicine 999 (Isselbacher, Adams, Braunwald, Petersdorf & Wilson eds, McGraw-Hill, pp. 999-1011; 9th ed. 1981). |
| “Guidance for Industry, S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization” (USFDA Oct. 2005). |
| FDA Center for Drug Evaluation and Research Data Standards Manual (Jan. 11, 2006). |
| Number | Date | Country | |
|---|---|---|---|
| 20060052429 A1 | Mar 2006 | US |
